NCT06550128

Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in HBeAg-negative CHB Subjects Under Stable Nucleos(t)Ide Analogue (NA) Treatment

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 86 (actual)
• Sponsor: Ausper Biopharma Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

AB-10-8003 is a randomized, multi-center phase II study to evaluate the efficacy and safety of AHB-137 in subjects with HBeAg-negative CHB under stable NA treatment.

Detailed description

The study is to evaluate the efficacy and safety of AHB-137 in HBeAg-negative CHB subjects. The total duration of the study, including screening phase, treatment phase and follow-up phase.

Conditions

• Hepatitis B, Chronic

Interventions

Type	Name	Description
DRUG	AHB-137	AHB-137 injection will be administered subcutaneously.
DRUG	AHB-137 and Placebo	AHB-137and placebo will be administered subcutaneously.
DRUG	AHB-137 (16weeks)	AHB-137 injection will be administered subcutaneously.

Timeline

• Start date: 2024-07-10
• Primary completion: 2026-02-02
• Completion: 2026-06-30
• First posted: 2024-08-12
• Last updated: 2025-11-26

Locations

6 sites across 1 country: China